Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Olutasidenib: from bench to bedside
Sangeetha Venugopal, Justin M. Watts
Blood Advances (2023) Vol. 7, Iss. 16, pp. 4358-4365
Open Access | Times Cited: 16

Showing 16 citing articles:

Contemporary Management of Acute Myeloid Leukemia
Sangeetha Venugopal, Mikkael A. Sekeres
JAMA Oncology (2024) Vol. 10, Iss. 10, pp. 1417-1417
Closed Access | Times Cited: 11
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Harry Fruchtman, Zachary M. Avigan, Julian A. Waksal, et al.
Leukemia (2024) Vol. 38, Iss. 5, pp. 927-935
Open Access | Times Cited: 10
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML)
Jorge E. Cortés, Brian A. Jonas, Gary J. Schiller, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 8, pp. 1145-1152
Open Access | Times Cited: 6
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia
Jorge E. Cortés
Expert Review of Hematology (2024) Vol. 17, Iss. 6, pp. 211-221
Open Access | Times Cited: 4
IDH-mutant gliomas in children and adolescents - from biology to clinical trials
Louise Evans, Sarah Trinder, Andrew Dodgshun, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Alexander W. Bray, Vaibhav Sahai
Current Oncology (2025) Vol. 32, Iss. 1, pp. 44-44
Open Access
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
Uwe Platzbecker, Richard A. Larson, Sandeep Gurbuxani
HemaSphere (2025) Vol. 9, Iss. 2
Open Access
Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist’s perspective
Yajun Jiang, Wen Gao
Frontiers in Pharmacology (2025) Vol. 16
Open Access
A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect
Yi‐Ru Bai, Xin Yang, Ken Chen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116759-116759
Closed Access | Times Cited: 3
Differentiation Syndrome in Acute Leukemia: APL and Beyond
Ashley Woods, Kelly J. Norsworthy
Cancers (2023) Vol. 15, Iss. 19, pp. 4767-4767
Open Access | Times Cited: 7
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
Sangeetha Venugopal, Justin M. Watts
Hematology (2023) Vol. 2023, Iss. 1, pp. 192-197
Closed Access | Times Cited: 7
Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia
Mihir Shukla, Maher Abdul‐Hay, Jun‐Hui Choi
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1768-1768
Open Access | Times Cited: 2
تأثير الطفرات في الـ IDH على مثيلة الدنا للجينات المرتبطة بسرطان الدم النخاعي الحاد: مقالة مراجعة
Duha Muhanad Bayram, Fadhel M. Lafta, Bassam Francis Matti
Journal of the Faculty of Medicine Baghdad (2024) Vol. 66, Iss. 1, pp. 116-125
Open Access | Times Cited: 1
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
Suvir Singh, Kunal Jain, Jagdeep Singh, et al.
Indian Journal of Medical and Paediatric Oncology (2024) Vol. 45, Iss. 02, pp. 115-126
Open Access
Page 1

Scroll to top